Literature DB >> 8721256

Urinary excretion of meperidine and normeperidine in man upon acute and chronic exposure to high altitude.

W A Ritschel1, C Paulos, A Arancibia, M Pezzani, M Agrawal, K Wetzelsberger, P W Lücker.   

Abstract

The urinary excretion of unchanged meperidine (M) varies with change of pH and metabolism. Since exposure of man to high altitude (H) may cause significant physiologic changes, we investigated its effects on the urinary excretion of M. The study was carried out in 3 groups of healthy, male volunteers (ages 18-20 years): at sea level (L), at 4360 m the day after arrival at H (HA), and at 4360 m in subjects residing for > 10 months at H (HC). Urine was collected for the periods of 0-4, 4-8, 8-12 and 12-24 h. Urinary pH was measured and the concentrations of M and normeperidine (N) were determined. The 24 h excretion of M and N was significantly decreased for L vs. HA and L vs. HC. Significance was also seen for the periods 0-4, 4-8 and 8-12 h. The ratio of amount excreted M/N for the 24 h period was highly significant for L vs. HA and L vs. HC. The urinary pH ranged from 5.3-5.9 for L, 5.9-7.0 for HA, and 5.1-5.7 for HC. The Fel (fraction of M eliminated in the unchanged form in urine) significantly decreased from L to HA and HC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8721256

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  2 in total

1.  Comparison of the pharmacokinetics of sulfamethoxazole in native Han and Tibetan male Chinese volunteers living at high altitude.

Authors:  Xiang-Yang Li; Yong-Nian Liu; Xue-Jun Wang; Jun-Bo Zhu; Ming Yuan; Yong-Ping Li; Yong-Fang Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-03-30       Impact factor: 2.441

2.  Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m).

Authors:  Michael Streit; Christoph Göggelmann; Christoph Dehnert; Jürgen Burhenne; Klaus-Dieter Riedel; Elmar Menold; Gerd Mikus; Peter Bärtsch; Walter E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2005-02-04       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.